(66 days)
Not Found
Not Found
No
The document describes a standard automated immunoassay analyzer and does not mention any AI or ML capabilities. The "Mentions AI, DNN, or ML" section is explicitly marked as "Not Found".
No
This device is a chemistry analyzer for in vitro diagnostic (IVD) use, intended to measure analytes, not to treat or cure a disease or condition.
Yes
Explanation: The "Intended Use / Indications for Use" section explicitly states that the device is a "discrete photometric chemistry analyzer for clinical use" and is "intended for use in conjunction with certain materials to measure a variety of analytes." Measurements of analytes in clinical settings are typically performed for diagnostic purposes.
No
The device description clearly indicates it is a "fully automated immunoassay analyzer" and mentions various hardware components and technologies (photometers, MEIA, FPIA, REA, IC). This is not a software-only device.
Based on the provided text, the device described is indeed an IVD (In Vitro Diagnostic). Here's why:
- Intended Use: The "Intended Use / Indications for Use" section explicitly states that the device is a "discrete photometric chemistry analyzer for clinical use" and is "intended for use in conjunction with certain materials to measure a variety of analytes." This clearly describes a device used to analyze samples in vitro (outside the body) to provide information for clinical purposes.
- Device Description: The description of the Abbott AxSYM System as a "fully automated immunoassay analyzer" that performs various immunoassay technologies (MEIA, FPIA, REA, IC) further confirms its role in analyzing biological samples in vitro.
- Clinical Use: The "Intended User / Care Setting" is listed as "clinical use," which is a common setting for IVD devices.
Therefore, the information provided strongly indicates that this device is an In Vitro Diagnostic.
N/A
Intended Use / Indications for Use
The Abbott AxSYM System is a fully automated immunoassay analyzer designed to perform Microparticle Enzyme Immunoassay (MEIA), Fluorescence Polarization Immunoassay (FPIA), Radiative Energy Attenuation (REA), and Ion Capture (IC) Immunoassay Technologies. The unique features of the AxSYM System allow it to perform random access, continuous access, and STAT processing of both large and small molecular weight analytes.
21 CFR § 862.2160 Discrete photometric chemistry analyzer for clinical use
(a) Identification. A discrete photometric chemistry analyzer for clinical use is a device intended to duplicate manual analytical procedures by performing automatically various steps such as pipetting, preparing filtrates, heating, and measuring color intensity. This device is intended for use in conjunction with certain materials to measure a variety of analytes. Different models of the device incorporate various instrumentation such as micro analysis apparatus, double beam, single, or dual channel photometers, and bichromatic 2wavelength photometers. Some models of the device may include reagent-containing components that may also serve as reaction units.
Product codes (comma separated list FDA assigned to the subject device)
JJE
Device Description
The Abbott AxSYM System is a fully automated immunoassay analyzer designed to perform Microparticle Enzyme Immunoassay (MEIA), Fluorescence Polarization Immunoassay (FPIA), Radiative Energy Attenuation (REA), and Ion Capture (IC) Immunoassay Technologies. The unique features of the AxSYM System allow it to perform random access, continuous access, and STAT processing of both large and small molecular weight analytes.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
When AxSYM MEIA, FPIA, Ion Capture and REA technologies were compared to AxSYM II using patient samples, correlation coefficients ranged from 0.98 to 0.99.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Abbott AxSYM II System
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 862.2160 Discrete photometric chemistry analyzer for clinical use.
(a)
Identification. A discrete photometric chemistry analyzer for clinical use is a device intended to duplicate manual analytical procedures by performing automatically various steps such as pipetting, preparing filtrates, heating, and measuring color intensity. This device is intended for use in conjunction with certain materials to measure a variety of analytes. Different models of the device incorporate various instrumentation such as micro analysis apparatus, double beam, single, or dual channel photometers, and bichromatic 2-wavelength photometers. Some models of the device may include reagent-containing components that may also serve as reaction units.(b)
Classification. Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.
0
15. 510(k) Summary - Abbott AxSYM® System
FEB | 2 1998
Summary of Safety and Effectiveness Information Supporting a Substantially Equivalent Determination
The following information presented in the 510(k) Notification for the Abbott AxSYM System supports a determination of substantial equivalence:
The Abbott AxSYM System is a fully automated immunoassay analyzer designed to perform Microparticle Enzyme Immunoassay (MEIA), Fluorescence Polarization Immunoassay (FPIA), Radiative Energy Attenuation (REA), and Ion Capture (IC) Immunoassay Technologies. The unique features of the AxSYM System allow it to perform random access, continuous access, and STAT processing of both large and small molecular weight analytes.
The Abbott AxSYM System is substantially equivalent to the Abbott AxSYM II System in that:
- a. Both systems may be used to perform assays for large and small molecular weight analytes.
- b. Both systems may be used to perform assays for therapeutic drugs.
- Both systems use Microparticle Enzyme Immunoas-ﻦ say (MEIA), Fluorescence Polarization Immunoassay (FPIA), and Ion Capture (IC) Immunoassay Technologies for the quantitation of antigen-antibody and protein binding reactions. Both systems use Radiative Energy Attenuation (REA) Assay Technology to quantitatively measure specific analyte concentrations.
- d. Both systems determine unknown concentrations of analytes from a standard curve generated with known analyte concentrations or qualitatively determine analyte concentrations by comparison to an established cutoff value.
- e. Both systems utilize a microprocessor for system control, data acquisition and data reduction.
1
- Both systems automatically process samples in a ranf. dom access mode (tests are processed in a random manner, dependent on the sample presented, and independent of the assay requested) as well as in a continuous access mode (samples may be presented for processing at any time the system is in operation). Both systems also have STAT capability.
When AxSYM MEIA, FPIA, Ion Capture and REA technologies were compared to AxSYM II using patient samples, correlation coefficients ranged from 0.98 to 0.99.
These data support the determination of substantial equivalence of the Abbott AxSYM System to the Abbott AxSYM II System.
Prepared and Submitted January 12, 1998 by:
Abbott Laboratories Patty O'Brien (847) 938-6563 Senior Regulatory Specialist ADD Regulatory Affairs 200 Abbott Park Road Abbott Park, Illinois 60064-3537
2
Image /page/2/Picture/1 description: The image is a black and white logo for the U.S. Department of Health and Human Services. The logo features a stylized caduceus, a symbol often associated with medicine and healthcare, with a double helix-like design. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the caduceus. The overall design is simple and professional, conveying the organization's focus on health and human welfare.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
FEB 1 2 1998
Patty O'Brien . Sr. Regulatory Specialist Abbott Laboratories 200 Abbott Park Road; D-9V6 AP31 Abbott Park, Illinois 60064-3537
Re : K974651 Abbott AxSYM System Requlatory Class: I Product Code: JJE Dated: December 5, 1997 December 8, 1997 Received:
Dear Ms. O'Brien:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions The general controls provisions of the Act of the Act. include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions aqainst misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major requlations affecting your device can be found in the Code of Federal Requlations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set " forth in the Quality System Requlation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP requlation may result in requlatory In addition, FDA may publish further announcements action. concerning your device in the Federal Register. Please note:
this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
3
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.
This letter will allow you to begin marketing your device as described in your 510 (k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to
premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".
Sincerely yours,
Steven Gutman
· Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
510(k) Number: K974651
Device Name: Abbott AxSYM® System
Indications For Use:
21 CFR § 862.2160 Discrete photometric chemistry analyzer for clinical use
(a) Identification. A discrete photometric chemistry analyzer for clinical use is a device intended to duplicate manual analytical procedures by performing automatically various steps such as pipetting, preparing filtrates, heating, and measuring color intensity. This device is intended for use in conjunction with certain materials to measure a variety of analytes. Different models of the device incorporate various instrumentation such as micro analysis apparatus, double beam, single, or dual channel photometers, and bichromatic 2wavelength photometers. Some models of the device may include reagent-containing components that may also serve as reaction units.
(b) Classification. Class I.
(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number K974651
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
| Prescription Use
(Per 21 CFR 801.109) | OR Over-The-Counter Use _
(Optional Format 1-2-96) |
| ------------------------------------------ | ------------------------------------------------------- |
|---|